Serum β -catenin levels associated with the ratio of RANKL/OPG in patients with postmenopausal osteoporosis

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Xu, Xiao Juan ^a   Shen, Lin ^a   Yang, Yan Ping ^a   Zhu, Rui ^a   Shuai, Bo ^a   Li, Cheng Gang ^a   Wu, Man Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TELOPEPTIDE; BETA CATENIN; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SCLEROSTIN;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84877963428     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/534352     Document Type: Article

References (39)

1. Day T. F., Guo X., Garrett-Beal L., Yang Y., Wnt/ β -catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005 8 5 739 750 2-s2.0-17844372752 10.1016/j.devcel.2005.03.016 (Pubitemid 40585296)
2. Jian H., Shen X., Liu I., Semenov M., He X., Wang X. F., Smad3-dependent nuclear translocation of β -catenin is required for TGF- β 1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes and Development 2006 20 6 666 674 2-s2.0-33645007189 10.1101/gad.1388806
3. Liu X. L., Li C. C., Liu K. J., Cui C. Y., Zhang Y. Z., Liu Y., The influence of fluoride on the expression of inhibitors of Wnt/ β -catenin signaling pathway in rat skin fibroblast cells. Biological Trace Element Research 2012 148 1 117 121 10.1007/s12011-012-9333-9
4. Semënov M., Tamai K., He X., SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. The Journal of Biological Chemistry 2005 280 29 26770 26775 2-s2.0-22844445934 10.1074/jbc.M504308200 (Pubitemid 41040710)
5. Ikeda T., Utsuyama M., Hirokawa K., Expression profiles of receptor activator of nuclear factor B ligand, receptor activator of nuclear factor B, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. Journal of Bone and Mineral Research 2001 16 8 1416 1425 2-s2.0-0034913371 (Pubitemid 32675193)
6. Hofbauer L. C., Khosla S., Dunstan C. R., Lacey D. L., Boyle W. J., Riggs B. L., The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 2000 15 1 2 12 2-s2.0-0033984313 (Pubitemid 30026926)
7. Arron J. R., Choi Y., Bone versus immune system. Nature 2000 408 6812 535 536 2-s2.0-0034735792 10.1038/35046196
8. Kobayashi Y., Udagawa N., Takahashi N., Action of RANKL and OPG for osteoclastogenesis. Critical Reviews in Eukaryotic Gene Expression 2009 19 1 61 72 10.1615/CritRevEukarGeneExpr.v19.i1.30
9. de Toni E. N., Thieme S. E., Herbst A., Behrens A., Stieber P., Jung A., Blum H., Göke B., Kolligs F. T., OPG is regulated by β -catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clinical Cancer Research 2008 14 15 4713 4718 2-s2.0-51049114701 10.1158/1078-0432.CCR-07-5019
10. Xiong J., O'Brien C. A., Osteocyte RANKL: new insights into the control of bone remodeling. Journal of Bone and Mineral Research 2012 27 3 499 505 10.1002/jbmr.1547
11. Wijenayaka A. R., Kogawa M., Lim H. P., Bonewald L. F., Findlay D. M., Atkins G. J., Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PloS ONE 2011 6 10 e25900
12. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 2-s2.0-0032540319 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
13. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H. L., Trall G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W. J., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 2 309 319 2-s2.0-0031005576 (Pubitemid 27199902)
14. Mulcahy L. E., Taylor D., Lee T. C., Duffy G. P., RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone 2011 48 2 182 188 2-s2.0-78650975236 10.1016/j.bone.2010.09.014
15. Chen B., Li X. D., Liu D. X., Wang H., Xie P., Liu Z. Y., Hou G. Q., Chang B., Du S. X., Canonical Wnt signaling is required for Panax notoginseng saponin-mediated attenuation of the RANKL/OPG ratio in bone marrow stromal cells during osteogenic differentiation. Phytomedicine 2012 19 11 1029 1034 10.1016/j.phymed.2012.06.002
16. Glass D. A. II, Bialek P., Ahn J. D., Starbuck M., Patel M. S., Clevers H., Taketo M. M., Long F., McMahon A. P., Lang R. A., Karsenty G., Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005 8 5 751 764 2-s2.0-20244373613 10.1016/j.devcel.2005.02. 017 (Pubitemid 40585297)
17. Spencer G. J., Utting J. C., Etheridge S. L., Arnett T. R., Genever P. G., Wnt signalling in osteoblasts regulates expression of the receptor activator of NF B ligand and inhibits osteoclastogenesis in vitro. Journal of Cell Science 2006 119 7 1283 1296 2-s2.0-33646808104 10.1242/jcs.02883
18. Gaudio A., Privitera F., Battaglia K., Torrisi V., Sidoti M. H., Pulvirenti I., Canzonieri E., Tringali G., Fiore C. E., Sclerostin levels associated with inhibition of the Wnt/ β -catenin signaling and reduced bone turnover in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2012 97 10 3744 3750 10.1210/jc.2012-1901
19. Johnson M. L., Kamel M. A., The Wnt signaling pathway and bone metabolism. Current Opinion in Rheumatology 2007 19 4 376 382 2-s2.0-34249978979 10.1097/BOR.0b013e32816e06f9 (Pubitemid 46884195)
20. Zhang R., Oyajobi B. O., Harris S. E., Chen D., Tsao C., Deng H. W., Zhao M., Wnt/ β -catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013 52 1 145 156
21. Baron R., Rawadi G., Roman-Roman S., Wnt signaling: a key regulator of bone mass. Current Topics in Developmental Biology 2006 76 103 127 2-s2.0-33751032130 10.1016/S0070-2153(06)76004-5 (Pubitemid 44760540)
22. Hartmann C., A Wnt canon orchestrating osteoblastogenesis. Trends in Cell Biology 2006 16 3 151 158 2-s2.0-33644828002 10.1016/j.tcb.2006.01.001 (Pubitemid 43358003)
23. Holmen S. L., Zylstra C. R., Mukherjee A., Sigler R. E., Faugere M. C., Bouxsein M. L., Deng L., Clemens T. L., Williams B. O., Essential role of β -catenin in postnatal bone acquisition. The Journal of Biological Chemistry 2005 280 22 21162 21168 2-s2.0-20444376156 10.1074/jbc.M501900200 (Pubitemid 40805677)
24. Krishnan V., Bryant H. U., MacDougald O. A., Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation 2006 116 5 1202 1209 2-s2.0-33646433058 10.1172/JCI28551
25. Gong Y., Slee R. B., Fukai N., Rawadi G., Roman-Roman S., Reginato A. M., Wang H., Cundy T., Glorieux F. H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S., Adkins W. N., Allgrove J., Arslan-Kirchner M., Batch J. A., Beighton P., Black G. C. M., Boles R. G., Boon L. M., Borrone C., Brunner H. G., Carle G. F., Dallapiccola B., De Paepe A., Floege B., Halfhide M. L., Hall B., Hennekam R. C., Hirose T., Jans A., Jüppner H., Kim C. A., Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M., Lemyre E., Letteboer T., Peltonen L., Ramesar R. S., Romanengo M., Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B., Superti-Furga A., Swoboda W., Van den Boogaard M. J., Van Hul W., Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B. R., Warman M. L., Warman M. L., LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 4 513 523 2-s2.0-18044386744 10.1016/S0092-8674(01)00571-2 (Pubitemid 33152786)
26. Kato M., Patel M. S., Levasseur R., Lobov I., Chang B. H. J., Glass D. A. II, Hartmann C., Li L., Hwang T. H., Brayton C. F., Lang R. A., Karsenty G., Chan L., Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. Journal of Cell Biology 2002 157 2 303 314 2-s2.0-0037092049 10.1083/jcb.200201089 (Pubitemid 34839826)
27. Takahashi N., Maeda K., Ishihara A., Uehara S., Kobayashi Y., Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Frontiers in Bioscience 2011 16 1 21 30 2-s2.0-79954483045 10.2741/3673
28. Gurban C. V., Mederle O., The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. Romanian Journal of Morphology and Embryology 2011 52 3, supplement 1113 1119
29. Winkler D. G., Sutherland M. K., Geoghegan J. C., Yu C., Hayes T., Skonier J. E., Shpektor D., Jonas M., Kovacevich B. R., Staehling-Hampton K., Appleby M., Brunkow M. E., Latham J. A., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 2003 22 23 6267 6276 2-s2.0-10744221383 10.1093/emboj/cdg599 (Pubitemid 37522584)
30. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S. E., Wu D., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. The Journal of Biological Chemistry 2005 280 20 19883 19887 2-s2.0-21244480924 10.1074/jbc.M413274200 (Pubitemid 41379516)
31. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B. M., Dellus H., Hoppe D., Stannek P., Walter C., Glinka A., Niehrs C., Kremen proteins are Dickkopf receptors that regulate Wnt/ β -catenin signalling. Nature 2002 417 6889 664 667 2-s2.0-0037030681 10.1038/nature756 (Pubitemid 34614827)
32. van Bezooijen R. L., Roelen B. A. J., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S. E., ten Dijke P., Löwik C. W. G. M., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 2004 199 6 805 814 2-s2.0-12144286871 10.1084/jem.20031454 (Pubitemid 38375200)
33. Ellies D. L., Viviano B., McCarthy J., Rey J. P., Itasaki N., Saunders S., Krumlauf R., Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. Journal of Bone and Mineral Research 2006 21 11 1738 1749 2-s2.0-33846449190 10.1359/jbmr.060810 (Pubitemid 46141229)
34. Gao Y., Wang H. Y., Casein kinase 2 is activated and essential for Wnt/ β -catenin signaling. The Journal of Biological Chemistry 2006 281 27 18394 18400 2-s2.0-33745865489 10.1074/jbc.M601112200 (Pubitemid 44035497)
35. Nusse R., Relays at the membrane. Nature 2005 438 7069 747 749 2-s2.0-28644448036 10.1038/438747a (Pubitemid 41753045)
36. Satow R., Shitashige M., Jigami T., Honda K., Ono M., Hirohashi S., Yamada T., Traf2- and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation. The Journal of Biological Chemistry 2010 285 34 26289 26294 2-s2.0-77956218106 10.1074/jbc.M109.090597
37. Shitashige M., Satow R., Jigami T., Aoki K., Honda K., Shibata T., Ono M., Hirohashi S., Yamada T., Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Research 2010 70 12 5024 5033 2-s2.0-77953775569 10.1158/0008-5472.CAN-10-0306
38. Ross S. E., Hemati N., Longo K. A., Bennett C. N., Lucas P. C., Erickson R. L., MacDougald O. A., Inhibition of adipogenesis by Wnt signaling. Science 2000 289 5481 950 953 2-s2.0-0034637103 10.1126/science.289.5481.950 (Pubitemid 30659947)
39. Bennett C. N., Ross S. E., Longo K. A., Bajnok L., Hemati N., Johnson K. W., Harrison S. D., MacDougald O. A., Regulation of Wnt signaling during adipogenesis. The Journal of Biological Chemistry 2002 277 34 30998 31004 2-s2.0-0037163113 10.1074/jbc.M204527200 (Pubitemid 34970803)